Literature DB >> 31262884

Perampanel Inhibits Neuroblastoma Cell Proliferation Through Down-regulation of AKT and ERK Pathways.

Akifumi Nozawa1, Michio Ozeki2, Mikako Matsuoka3, Mina Nakama1,4, Shiho Yasue1, Saori Endo1, Norio Kawamoto1, Hidenori Ohnishi1, Toshiyuki Fukao1,4.   

Abstract

BACKGROUND/AIM: Activation of AKT serine/ threonine kinase (AKT) predicts poor outcome in neuroblastoma, which highlights the potential of the AKT pathway as a promising target for neuroblastoma treatment. Several studies reported that blockade of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors (AMPARs) reduces proliferation in glioblastoma or lung cancer by inhibiting AKT and extracellular signal-related kinase (ERK) pathways. In this study, we examined the effect of the AMPAR antagonist perampanel on human neuroblastoma cells.
MATERIALS AND METHODS: Cell proliferation, caspase activity, and western blot assays were performed to determine the effect of perampanel on the KP-N-SI9s human neuroblastoma cell line.
RESULTS: Perampanel inhibited cell proliferation without triggering apoptosis in neuroblastoma cells. Down-regulation of AKT protein levels, AKT phosphorylation, and ERK1/2 phosphorylation were also observed in neuroblastoma cells with perampanel treatment.
CONCLUSION: Perampanel inhibits neuroblastoma cell proliferation through down-regulation of AKT and ERK pathways and has potential for the treatment of neuroblastoma. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  AMPA receptor; AMPAR antagonist; Pediatric oncology; glutamate receptors; molecular targeted therapy

Mesh:

Substances:

Year:  2019        PMID: 31262884     DOI: 10.21873/anticanres.13506

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Perampanel Add-on to Standard Radiochemotherapy in vivo Promotes Neuroprotection in a Rodent F98 Glioma Model.

Authors:  Falko Lange; Jens Hartung; Clara Liebelt; Julius Boisserée; Tobias Resch; Katrin Porath; Julia Hörnschemeyer; Gesine Reichart; Tina Sellmann; Valentin Neubert; Stephan Kriesen; Guido Hildebrandt; Elisabeth Schültke; Rüdiger Köhling; Timo Kirschstein
Journal:  Front Neurosci       Date:  2020-11-30       Impact factor: 4.677

2.  A National Consensus Survey for Current Practice in Brain Tumor Management I: Antiepileptic Drug and Steroid Usage.

Authors:  Sung Kwon Kim; Jangsup Moon; Jin Mo Cho; Chul Kee Park; Youn Soo Lee; Ho Shin Gwak; Kyung Hwan Kim; Se Hoon Kim; Young Il Kim; Young Zoon Kim; Ho Sung Kim; Yun Sik Dho; Jae Sung Park; Ji Eun Park; Youngbeom Seo; Kyoung Su Sung; Jin Ho Song; Chan Woo Wee; Wan Soo Yoon; Hong In Yoon; Se Hoon Lee; Do Hoon Lim; Jung Ho Im; Jong Hee Chang; Myung Hoon Han; Je Beom Hong; Kihwan Hwang
Journal:  Brain Tumor Res Treat       Date:  2020-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.